In a phase 3 trial of 2,339 non-diabetic adults with obesity, once-weekly retatrutide (a GIP, GLP-1 and glucagon receptor agonist) cut body weight by a mean of 25.0% at 12 mg over 80 weeks, vs 3.9% on placebo. It also reduced knee osteoarthritis pain and apnea-hypopnea events.
#MedSky #obesity
frontierresearch.co
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity | Frontier
Retatrutide activates the receptors for three hormones: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon.